Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

87.89 +0.59 (+0.68%)
Streaming Delayed Price Updated: 2:57 PM EDT, Oct 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 960,707
Open 87.40
Bid (Size) 87.88 (1)
Ask (Size) 87.92 (1)
Prev. Close 87.30
Today's Range 87.25 - 88.11
52wk Range 53.56 - 92.86
Shares Outstanding 222,430,635
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
INCYTE CORP (NASDAQ:INCY) Presents a Value Investing Opportunity with Strong Fundamentals
INCYTE CORP (INCY) appears undervalued with strong profitability and a healthy balance sheet. Its low P/E and high ROE suggest a potential value investing opportunity. 
Via Chartmill
These S&P500 stocks are gapping in today's session
Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Monday. Discover the gap up and gap down stocks in the S&P500 index. 
Via Chartmill

Performance

YTD
+26.4%
+26.4%
1 Month
+3.7%
+3.7%
3 Month
+27.6%
+27.6%
6 Month
+53.2%
+53.2%
1 Year
+34.7%
+34.7%

More News

Read More
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma
From Incyte
Via Business Wire
Incyte (INCY) Stock Is Up, What You Need To Know
Via StockStory
Topics Artificial Intelligence
Incyte's (INCY) EVP and General Counsel Sold 4,100 Shares for $352,000
Via The Motley Fool
Topics Regulatory Compliance
Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025
From Incyte
Via Business Wire
JPMorgan Elevates Incyte Price Target Amidst Robust Pipeline and Commercial Success, Yet Maintains Cautious "Neutral" Stance
Via MarketMinute
Topics Economy Intellectual Property
What 14 Analyst Ratings Have To Say About Incyte
Via Benzinga
Which S&P500 stocks are gapping on Wednesday?
Via Chartmill
Incyte to Report Third Quarter Financial Results
From Incyte
Via Business Wire
2 Reasons to Like INCY and 1 to Stay Skeptical
Via StockStory
Topics Stocks
Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes
Via MarketMinute
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
STRATA Skin Sciences Soars as Landmark Study Reveals Superior Vitiligo Treatment Efficacy
Via MarketMinute
Topics Intellectual Property
Jim Cramer Spotlights These Undervalued S&P 500 Stocks With Growth Potential Amid Skyrocketing Market
Via Benzinga
Topics Stocks
Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer
From Incyte
Via Business Wire
Incyte Stock: A Deep Dive Into Analyst Perspectives (11 Ratings)
Via Benzinga
FDA Expands Incyte's Opzelura Approval To Treat Atopic Dermatitis In Children
Via Benzinga
Incyte Corp (NASDAQ:INCY) Emerges as a Top Value Investing Candidate
Via Chartmill
Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis
From Incyte
Via Business Wire
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025
From Incyte
Via Business Wire
2 S&P 500 Stocks with Exciting Potential and 1 We Avoid
Via StockStory
Topics Stocks
Uncover the latest developments among S&P500 stocks in today's session.
Via Chartmill
3 Unpopular Stocks That Deserve a Second Chance
Via StockStory
Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress
From Incyte
Via Business Wire

Frequently Asked Questions

Is Incyte Corporation - Common Stock publicly traded?
Yes, Incyte Corporation - Common Stock is publicly traded.
What exchange does Incyte Corporation - Common Stock trade on?
Incyte Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Incyte Corporation - Common Stock?
The ticker symbol for Incyte Corporation - Common Stock is INCY on the Nasdaq Stock Market
What is the current price of Incyte Corporation - Common Stock?
The current price of Incyte Corporation - Common Stock is 87.89
When was Incyte Corporation - Common Stock last traded?
The last trade of Incyte Corporation - Common Stock was at 10/22/25 02:57 PM ET
What is the market capitalization of Incyte Corporation - Common Stock?
The market capitalization of Incyte Corporation - Common Stock is 19.55B
How many shares of Incyte Corporation - Common Stock are outstanding?
Incyte Corporation - Common Stock has 20B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.